XERS - Company ID 0001867096
The table below shows Xeris Biopharma Holdings, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $9.87M | -$10.03M | -$20.30M | -$26.14M | -$48.41M | -$23.96M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$325.00K | -$13.00K | -$19.65M | -$43.98M | $6.72M | $26.30M |
| Dividends paid | - | - | - | - |
Xeris Biopharma Holdings, Inc. reported operating cash flow of $28.63M for fiscal year 2025. That is up 177.4% from -$36.98M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$80.56M (FY 2020) to $28.63M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$8.84M | -$3.14M | $35.19M | -$863.00K | $78.19M | $26.66M |